ReviewEuropean urology focus2023
Bladder Cancer Carcinogens: Opportunities for Risk Reduction.
Review in European urology focus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.Research square · 2026Article
- A molecular landscape tracking the progression of non-muscle invasive bladder cancer.World journal of urology · 2026Review
- Overview of tumor-resident intratumoral microbiota in human bladder cancer.Translational andrology and urology · 2026Article
- Article
- GLRX2 polymorphism and oxidative stress levels impact urothelial bladder cancer outcomes.Scientific reports · 2025Article
- Emerging Biomarkers in Urological Cancers: Angiogenesis and Damage-Associated Molecular Pattern Signaling.International journal of molecular sciences · 2025Review
- Trends in genitourinary tumors: Academic center experience over 16 years.Saudi medical journal · 2025Article
- Article
- CircRNA_103809/miR-516a/FBXL18 contributes to stemness and gemcitabine resistance of bladder cancer cells.Archives of medical science : AMS · 2025Article
- Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer.Frontiers in oncology · 2025Review
- Dynamic changes of urinary microbiota in patients with bladder cancer after surgery and its clinical significance.Frontiers in immunology · 2025Review
- Risk Factors Associated with Urothelial Bladder Cancer.International journal of environmental research and public health · 2024Review
- From TURP to enucleation: navigating the complex relationship between BPH treatments and bladder cancer.World journal of urology · 2024Article
- Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.Biology direct · 2024Article
- Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-κB pathways.Apoptosis : an international journal on programmed cell death · 2024Article
- Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement.International journal of molecular sciences · 2024Review
- The role of microbiota in tumorigenesis, progression and treatment of bladder cancer.Microbiome research reports · 2024Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Bladder cancer at an individual level is likely to be the consequence of repeated, long-term exposure to one or more known bladder carcinogens, some of which are endemic or unavoidable in daily life, in addition to host factors. This Mini-Review highlights exposures that are associated with higher risk of bladder cancer, summarizes the evidence for each association, and suggests strategies to decrease risk at both individual and population levels. PATIENT SUMMARY: Tobacco smoking, exposure to certain chemicals in your diet, environment, or workplace, urinary infections, and certain medications can increase your risk of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.